Neurology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Correspondence:
Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Arnold, D. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Arnold, D. L.
NEUROLOGY 2007;68:S83-S90
© 2007 American Academy of Neurology

Evidence for neuroprotection and remyelination using imaging techniques

Douglas L. Arnold, MD

From the Department of Neurology and Neurosurgery, Montreal Neurological Institute and Hospital, McGill University, Montreal, Quebec, Canada.

Address correspondence and reprint requests to Dr. Douglas L. Arnold, Montreal Neurological Institute, 3801 University Street, Montreal, Quebec, H3A 2B4, Canada doug{at}mrs.mni.mcgill.ca

MRI is used routinely in clinical practice and pharmaceutical trials to measure disease activity and assess the effects of treatment in multiple sclerosis. Conventional MRI techniques sensitively detect inflammation, demyelination, and tissue injury. Less conventional imaging modalities, such as magnetic resonance spectroscopy and magnetization transfer imaging, and advanced image processing to quantify structural changes can provide more specific and inherently quantitative markers of the pathologic processes underlying the accumulation of disease burden and the progression of clinical disability. Together, these techniques can assess both the anti-inflammatory and the neuroprotective effects of immunomodulatory therapies.


This supplement was supported by an educational grant from Teva Neuroscience. BioScience Communications contributed to the editorial refinement of this article and to the production of this supplement. Authors may have accepted honoraria for their supplement contributions.

Disclosure:. The author reports no conflict of interest.

Neurology supplements are not peer-reviewed. Information contained in Neurology supplements represents the opinions of the authors and is not endorsed by nor does it reflect the views of the American Academy of Neurology, Editorial Board, Editor-in-Chief, or Associate Editors of Neurology.




This article has been cited by other articles:


Home page
NeurologyHome page
G. Birnbaum, T. P. Leist, and F. D. Lublin
Commentary II: Clinical aspects of assessing neuronal health in multiple sclerosis
Neurology, May 29, 2007; 68(22_suppl_3): S55 - S57.
[Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2007 by AAN Enterprises, Inc.